An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer

An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer

A wide inter-individual variability in the therapeutic response to cyclin-dependent kinases 4 and 6 inhibitors (CDKis) has been reported. We herein present a case series of five patients treated with either palbociclib or ribociclib referred to our clinical pharmacological counselling, including the...

Full description

Bibliographic Details
Main Authors:	Rossana Roncato, Lorenzo Gerratana, Lorenza Palmero, Sara Gagno, Ariana Soledad Poetto, Elena Peruzzi, Martina Zanchetta, Bianca Posocco, Elena De Mattia, Giovanni Canil, Martina Alberti, Marco Orleni, Giuseppe Toffoli, Fabio Puglisi, Erika Cecchin
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-07-01
Series:	Frontiers in Pharmacology
Subjects:	personalized medicine TDM polymorphisms pharmacological counselling breast cancer CDK4/6 inhibitors
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.897951/full

Similar Items

Increased plasma imatinib exposure and toxicity in chronically treated GIST patients with SARS-CoV-2 infection: a case series
by: Sara Gagno, et al.
Published: (2024-10-01)

CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
by: Mattia Garutti, et al.
Published: (2021-05-01)

Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug–gene interactions
by: Elena Peruzzi, et al.
Published: (2024-09-01)

A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring
by: Martina Zanchetta, et al.
Published: (2021-01-01)

A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring.
by: Martina Zanchetta, et al.
Published: (2021-01-01)

Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application.
by: Bianca Posocco, et al.
Published: (2020-01-01)

First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study
by: Debora Basile, et al.
Published: (2021-06-01)

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them
by: L. Foffano, et al.
Published: (2025-02-01)

LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring
by: Giovanni Canil, et al.
Published: (2023-05-01)

The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs
by: Amanda C. Sharko, et al.
Published: (2021-01-01)

Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients.
by: Valentina Iacuzzi, et al.
Published: (2019-01-01)

NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome
by: Anna Michelotti, et al.
Published: (2021-08-01)

CDK5: an oncogene or an anti-oncogene: location location location
by: Kumar Nikhil, et al.
Published: (2023-11-01)

Molecular and in vivo Functions of the CDK8 and CDK19 Kinase Modules
by: Marius Volker Dannappel, et al.
Published: (2019-01-01)

Identifying Cancers Impacted by CDK8/19
by: Igor B. Roninson, et al.
Published: (2019-08-01)

Altered expression of the Cdk5 activator-like protein, Cdk5α, causes neurodegeneration, in part by accelerating the rate of aging
by: Joshua Spurrier, et al.
Published: (2018-03-01)

Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
by: Mei Zeng, et al.
Published: (2018-11-01)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
by: Ran Sun, et al.
Published: (2022-04-01)

A nationwide utilization survey of therapeutic drug monitoring for five antibiotics in South Korea
by: Choi R, et al.
Published: (2019-07-01)

Dual Inhibition of CDK4/6 and CDK7 Suppresses Triple‐Negative Breast Cancer Progression via Epigenetic Modulation of SREBP1‐Regulated Cholesterol Metabolism
by: Yilan Yang, et al.
Published: (2025-02-01)

Characterizing CDK8/19 Inhibitors through a NFκB-Dependent Cell-Based Assay
by: Jing Li, et al.
Published: (2019-10-01)

Cell cycle-dependent binding between Cyclin B1 and Cdk1 revealed by time-resolved fluorescence correlation spectroscopy
by: Martina Barbiero, et al.
Published: (2022-06-01)

Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers
by: Shaian Tavakolian, et al.
Published: (2020-05-01)

CDK16 promotes the progression and metastasis of triple-negative breast cancer by phosphorylating PRC1
by: Xiao Li, et al.
Published: (2022-04-01)

CDK12/CDK13: New Hope for Targeted Therapy of Human Malignant Tumors
by: CHEN Kaixing, et al.
Published: (2024-05-01)

Inhibition of Cdk8/Cdk19 Activity Promotes Treg Cell Differentiation and Suppresses Autoimmune Diseases
by: Zengli Guo, et al.
Published: (2019-08-01)

Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review
by: Ioana-Miruna Stanciu, et al.
Published: (2023-04-01)

CDK7 Inhibition is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition
by: Martina S.J. McDermott, et al.
Published: (2020-03-01)

The role of Cdk5 in neurological disorders
by: Chuncao Ao, et al.
Published: (2022-07-01)

Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer
by: Navid Sobhani, et al.
Published: (2021-02-01)

Sex Differences on Mitotane Concentration and Treatment Outcome in Patients with Adrenocortical Carcinoma
by: Sarah Allegra, et al.
Published: (2021-03-01)

Identification of new inhibitors of the kinase activity of CDK2 and CDK9 by molecular modeling and high-efficiency screening
by: G.V. Andrianov, et al.
Published: (2021-12-01)

The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors
by: Federico Sottotetti, et al.
Published: (2022-09-01)

Characterization and functional analysis of chicken CDK protein
by: Zhixuan Xiong, et al.
Published: (2024-07-01)

p53–GSDME Elevation: A Path for CDK7 Inhibition to Suppress Breast Cancer Cell Survival
by: Yueyuan Wang, et al.
Published: (2021-08-01)

Identification of Enhancer RNA CDK6-AS1 as a Potential Novel Prognostic Biomarker in Gastric Cancer
by: Shifeng Yang, et al.
Published: (2022-04-01)

An RB insensitive to CDK regulation
by: Manel Joaquin, et al.
Published: (2017-01-01)

Estradiol regulates oxidative stress and angiogenesis of myocardial microvascular endothelial cells via the CDK1/CDK2 pathway
by: Ke Zhou, et al.
Published: (2023-03-01)

Compartmentalized control of Cdk1 drives mitotic spindle assembly
by: Angela Flavia Serpico, et al.
Published: (2022-01-01)

Cdk6: At the interface of Rb and p53
by: Sofie Nebenfuehr, et al.
Published: (2018-09-01)